

Kidney Suite Guideline Update - Committee Meeting

Date: 30/01/2020 & 31/01/2020

Location: Day 1 - Avonmouth House- London
Day 2 – NICE offices London

Minutes: Final

Committee members present:	
Anthony Wierzbicki (AW)	Day 1 Present for notes 1 – 6 Day 2 Present for notes 1 – 10
Sarah Ali (SA)	Day 1 Present for notes 1 –6
Clare Allinson (CA)	Day 1 Present for notes 1 – 6 Day 2 Present for notes 1 – 10
Virginia Aylett (VA)	Day 1 Present for notes 1 – 6 Day 2 Present for notes 1 – 10
Tara Bashford (TB)	Day 1 Present for notes 1 – 6 Day 2 Present for notes 1 – 10
Ivan Benett (IB)	Day 1 Present for notes 1 – 6 Day 2 Present for notes 1 – partway through item 7
Roy Connell (RC)	Day 1 Present for notes 1 – 6 Day 2 Present for notes 1 – 10
Jan Dudley (JD)	Day 1 Present for notes 1 – 6 Day 2 Present for notes 1 – partway through item 7
Andrew Farmer (AF)	Day 1 Present for notes 1 –6
Hugh Gallagher (HG)	Day 1 Present for notes 1 –6
Arif Khwaja (AK)	Day 1 Present for notes 1 – 6 Day 2 Present for notes 1 – 10
Andrew Lewington (AL)	Day 1 Present for notes 1 – 6 Day 2 Present for notes 1 – 10
Fiona Loud (FL)	Day 1 Present for notes 1 –6
Nicola Thomas (NT)	Day 1 Present for notes 1 – 6 Day 2 Present for notes 1 – 10
Rajib Pal (RP)	Day 1 Present for notes 1 –6
Catherine Pogson (CP)	Day 1 Present for notes 1 – 6

Kidney Suite GComm 7 minutes

	Day 2 Present for notes 1 – 10
--	--------------------------------

In attendance:		
Chris Carmona (CC)	Senior Technical Analyst	Day 1 Present for notes 1 – 6 Day 2 Present for notes 1 – 10
James Hall (JH)	Editor	Day 1 Present for notes 1 – 6
Justine Karpusheff (JK)	Commissioning Manager	Day 1 Present for notes 1 – 6 Day 2 Present for notes 1 – 3
Yolanda Martinez (YM)	Technical Analyst	Day 1 Present for notes 1 – 6 Day 2 Present for notes 1 – 10
Rui Martins (RM)	Technical Analyst - Health Economics	Day 2 Present for notes 1 –
Vonda Murray (VM)	Project Manager	Day 1 Present for notes 1 – 6 Day 2 Present for notes 1 – 10
Joshua Pink (JP)	Technical Adviser – Health Economics	Day 1 Present for notes 1 – 6
Susan Spiers (SP)	Associate Director	Day 1 Present for notes 1 – 6 Day 2 Present for notes 1 – 4

Apologies:	
Sarah Ali	Committee member – day 2
Grainne Connolly	Committee member – day 1 & 2
Andrew Farmer	Committee member – day 2
Hugh Gallagher	Committee member – day 2
Deepa Kariyawasam	Committee member – day 1 & 2
Fiona Loud	Committee member – day 2
Rui Martins	NICE, Technical Analyst - Health Economics – day 1
Rajib Pal	Committee member – day 2
Joshua Pink	NICE - Technical Adviser – Health Economics– day 2

Observer:	
Jeremy Dietz	Technical Analyst – Health Economics – Day1

1. Welcome and objectives for the meeting

Kidney Suite GComm 7 minutes

The Chair welcomed the committee members and attendees to the 1st day of the 7th committee meeting on Kidney Injury & Disease. The Chair welcomed to the committee; SA, AF, and GH. The Chair, committee members, and NICE attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Understanding the role of the Editor and the role they play in guideline development.
- Review and discussion of the evidence for people with/suspected chronic kidney disease on the effect of interventions to lower proteinuria.
- Review and discussion of the evidence for people with chronic kidney disease, what are the optimal blood pressure ranges for slowing kidney disease progression and reducing cardiovascular disease risk and mortality.
- Discussion on economic modelling.

The Chair asked all committee members to verbally declare any interests that have arisen since the last meeting. The Chair and senior members of the Developer team noted that the interests previously declared, and any new interests did not prevent the attendees from fully participating in the meeting. New interests are noted below;

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Fiona Loud	Lay member	Speaking at European Parliament, in March about organ donation. Travel costs paid by the European Kidney Health Alliance	Direct financial	Declare and Participate
Fiona Loud	Lay member	Speaking at British Transplant Society Conference in Belfast, in March, on organ donation. Travel costs and overnight accommodation paid by Astellas. Honorarium donated to charity.	Direct financial	Declare and Participate
Fiona Loud	Lay member	Speaking at International Society	Direct financial	Declare and

Kidney Suite GComm 7 minutes

		<p>of Nephrology conference in Abu Dhabi on organ donation, in March. Travel and accommodation paid by the International Society of Nephrology.</p>		Participate
<p>The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.</p>				
<p>2. The role of the Editor</p>				
<p>The Chair introduced JH, Editor, for the guideline, who gave a presentation on the what the role of the Editor is, and how they can help with the development of the guideline. The Chair thanked JH for their presentation.</p>				
<p>3. RQ2.3 For adults, children and young people with suspected or diagnosed CKD, what is the effect of interventions to lower proteinuria?</p> <ul style="list-style-type: none"> • Clinical evidence • Health economic evidence • Diabetes recommendations 				
<p>The Chair introduced YM, Technical Analyst, and JP Technical Adviser (Health Economics), who gave a presentation on the clinical and health economic evidence for people with/suspected chronic kidney disease on the effect of interventions to lower proteinuria. The committee discussed the evidence presented. The Chair thanked YM and JP for their presentation.</p>				
<p>4. RQ4.1 In adults, children and young people with CKD, what are the optimal blood pressure ranges for slowing kidney disease progression, and for reducing cardiovascular disease risk and mortality?</p> <ul style="list-style-type: none"> • Presentation of clinical evidence 				
<p>The Chair introduced CC, Senior Technical Analyst, who gave a presentation on the clinical evidence for people with chronic kidney disease, what are the optimal blood pressure ranges for slowing kidney disease progression and reducing cardiovascular disease risk and mortality. The committee discussed the evidence presented. The Chair thanked CC for his presentation.</p>				
<p>5. RQ4.1 In adults, children and young people with CKD, what are the optimal</p>				

Kidney Suite GComm 7 minutes

blood pressure ranges for slowing kidney disease progression, and for reducing cardiovascular disease risk and mortality?

- **Diabetes recommendations**

The committee discussed the evidence presented.

6. Health economic modelling

The Chair introduced JP Technical Adviser (Health Economics), who led a discussion on health economic modelling for the guideline. The Chair, thanked JP for leading the discussion.

5. AOB

No other business to discuss

6. Summary and next steps

The Chair thanked the committee for their time and contribution to the meeting and reminded the committee of the start time of day 2 of the meeting.

Kidney Suite GComm 7 minutes

Day 2 – Friday 31st January 2020

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to day 2, of the 7th meeting on Kidney Injury & Disease.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Review and discussion of the evidence for people with chronic kidney disease the accuracy of cystatin C-based equations to estimate GFR as a measurement of kidney function.
- Resolve outstanding queries for the evidence on people with chronic kidney disease for people with stage 5 CKD who are on dialysis, what amount of IV iron is most clinically and cost effective in managing anaemia and its associated outcomes
- Agree on how best to answer manage the review questions on people with chronic kidney disease what constitutes a clinically significant decline in eGFR and what is the optimal monitoring frequency based on different rates of decline in eGFR in terms of risk of kidney disease progression
- Recommendation discussion on people with suspected/ diagnosed chronic kidney disease on the effect of interventions to lower proteinuria?
- Recommendation discussion on people with chronic kidney disease for people on what the optimal blood pressure ranges for slowing kidney disease progression, and for reducing cardiovascular disease risk and mortality
- Resolve queries on a review question protocol.
- Share with the committee which review questions, will be presented at future committee meetings.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting, no new interests were declared.

2. RQ1.1 What is the accuracy of cystatin C-based equations to estimate GFR as a measurement of kidney function in adults, children and young people?

- **Presentation of clinical evidence**
- **Draft recommendations**

The Chair introduced YM, Technical Analyst, who gave a presentation on the clinical evidence for evidence for people with chronic kidney disease the accuracy of cystatin C-based equations to estimate GFR as a measurement of kidney function. The committee discussed the evidence presented. The Chair thanked YM for her presentation.

Kidney Suite GComm 7 minutes

3. RQ8.1 For people with stage 5 CKD who are on dialysis, what amount of IV iron is most clinically and cost effective in managing anaemia and its associated outcomes?

- Discussion
- Resolution of outstanding comments

The Chair introduced CC, Senior Technical Analyst, who gave a presentation on outstanding comments for the clinical evidence and recommendations for people with stage 5 CKD who are on dialysis, what amount of IV iron is most clinically and cost effective in managing anaemia and its associated outcomes. The committee discussed the evidence presented. The Chair thanked CC for his presentation.

4. RQ3.1 For adults, children and young people with CKD, what constitutes a clinically significant decline in eGFR in terms of risk of kidney disease progression?

RQ3.2 For adults, children and young people with CKD what is the optimal monitoring frequency based on different rates of decline in eGFR?

- Discussion about how best to manage these questions

The Chair introduced CC, Senior Technical Analyst, who gave a presentation on the review questions for people with chronic kidney disease what constitutes a clinically significant decline in eGFR and what is the optimal monitoring frequency based on different rates of decline in eGFR in terms of risk of kidney disease progression. The Chair thanked CC for his presentation and facilitated a committee discussion.

5. RQ2.3 For adults, children and young people with suspected or diagnosed CKD, what is the effect of interventions to lower proteinuria?

- Recommendation discussion

Since there were no outstanding discussions relating to RQ2.3, the Chair moved to the next item.

6. RQ4.1 In adults, children and young people with CKD, what are the optimal blood pressure ranges for slowing kidney disease progression, and for reducing cardiovascular disease risk and mortality?

- Recommendation discussion

Since there were no outstanding discussions relating to RQ4.1, the Chair moved to the next item.

7. Protocols

The Chair introduced CC, Senior Technical Analyst, who provided a presentation on queries the technical team had on a number of protocols. The Chair thanked CC for his presentation and facilitated a committee discussion.

Kidney Suite GComm 7 minutes

8. RQ's mapped to remaining committee meetings

The Chair introduced CC, Senior Technical Analyst, who provided a presentation on which review questions would be presented at which meeting. The Chair thanked CC for his presentation.

9. AOB

No other business to discuss

10. Summary and next steps

The Chair thanked the committee for their time and contribution to the meeting. The venue, date and time of the next meeting was confirmed

Date of next meeting: 09/03/2020

Location of next meeting: NICE offices – Manchester